Epic Sciences, a San Diego, CA-based developer of blood tests that predict therapeutic benefit for cancer patients, completed a $52m Series E financing.
The round was led by Blue Ox Healthcare Partners, with participation from Deerfield Management and Varian (NYSE : VAR ) and existing investors Altos Capital Partners, Genomic Health, Inc., Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management.
The company intends to use the funds to advance liquid biopsy tests to predict drug response in cancer patients and to integrate its No Cell Left Behind platform with electronic medical records and big data analytics.
Led by Murali Prahalad, Ph.D., president and CEO, Epic Sciences is developing novel diagnostics to personalize and advance the treatment and management of cancer. The company aims to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. Epic leverages a platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Its No Cell Left Behind® technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, the company partners with pharmaceutical companies and major cancer centers around the world to commercialize the technology.